Biotech Values

[DewDiligence]

The price of a deal may have gone up too. I guess that's not an issue for a company that prints money.

In all likelihood, we’re talking about a licensing deal, not a buyout, so I don’t see why the price of a deal would have gone up just because Bischofberger said GILD was in discussions with several companies. To the contrary, Bischofberger’s CC comment might cause the prospective licensors to bid against themselves, thereby lowering GILD’s deal price. All told, however, I think the subject of this thread is a non-issue.